详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

Schisandrin B Inhibits Osteoclastogenesis and Protects Against Ovariectomy-Induced Bone Loss

90| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

单位： [1]Huazhong Univ Sci & Technol,Dept Orthoped,Tongji Hosp,Tongji Med Coll,Wuhan,Peoples R China

出处：

DOI：

ISSN：

关键词： Schisandrin B osteoclast osteoporosis MAPK NF-kappa B Nrf2

摘要：

Osteoporosis is a systemic skeletal disease which is highly prevalent worldwide and considered to be associated with excessive bone resorption mediated by osteoclast. Osteoclast differentiation is featured by the activation of inflammation-related pathways and the generation of reactive oxygen species. Schisandrin B is a bioactive compound with strong antiinflammation and antioxidative properties, we thus speculated that Schisandrin B might serve as a potential candidate for osteoporosis. In the present study, we found that the formation and` function of osteoclasts were dramatically suppressed by Schisandrin B. And consistent with thein vitroresults, treatment with Schisandrin B attenuated ovariectomy-induced bone loss in mice. Moreover, Schisandrin B notably inhibited the activation of mitogen activated protein kinase (MAPK) and nuclear factor-kappa B (NF-kappa B) pathways and scavenged ROS by activating nuclear factor E2 p45-related factor 2 (Nrf2) signaling. In conclusion, our study indicates that Schisandrin B is an effective approach to treat osteoporosis and other osteoclast-related diseases.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2019]版：

大类 | 2 区医学

小类 | 2 区药学

最新[2025]版：

大类 | 3 区医学

小类 | 3 区药学

JCR分区：

出版当年[2018]版：

Q1 PHARMACOLOGY & PHARMACY

最新[2023]版：

Q1 PHARMACOLOGY & PHARMACY

影响因子： 4.4 最新[2023版] 5 最新五年平均 3.845 出版当年[2018版] 4.469 出版当年五年平均 3.831 出版前一年[2017版] 4.225 出版后一年[2019版]

第一作者：

第一作者单位： [1]Huazhong Univ Sci & Technol,Dept Orthoped,Tongji Hosp,Tongji Med Coll,Wuhan,Peoples R China

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Isofraxidin Inhibits Receptor Activator of Nuclear Factor-kappa B Ligand-Induced Osteoclastogenesis in Bone Marrow-Derived Macrophages Isolated from Sprague-Dawley Rats by Regulating NF-kappa B/NFATc1 and Akt/NFATc1 Signaling Pathways [2]Dihydromyricetin Protects against Bone Loss in Ovariectomized Mice by Suppressing Osteoclast Activity [3]Epoxyeicosanoids suppress osteoclastogenesis and prevent ovariectomy-induced bone loss [4]Pristimerin Suppresses RANKL-Induced Osteoclastogenesis and Ameliorates Ovariectomy-Induced Bone Loss [5]Effects of Taxifolin on Osteoclastogenesis in vitro and in vivo [6]GAG and collagen II attenuate glucocorticoid-induced osteoporosis by regulating NF-κB and MAPK signaling [7]Ulinastatin Inhibits Osteoclastogenesis and Suppresses Ovariectomy-Induced Bone Loss by Downregulating uPAR [8]GAG and collagen II attenuate glucocorticoid-induced osteoporosis by regulating NF-κB and MAPK signaling. [9]Schisandrin A Inhibits the IL-1β-Induced Inflammation and Cartilage Degradation via Suppression of MAPK and NF-κB Signal Pathways in Rat Chondrocytes [10]PKC theta Regulates Pituitary Adenoma Bone Invasion by Activating Osteoclast in NF-kappa B/IL-1 beta-Dependent Manner